Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Heart Failure Reports
Published in: Current Heart Failure Reports 6/2017

01-12-2017 | Pharmacologic Therapy (W H W Tang, Section Editor)

Prevention and Treatment of Thrombotic and Hemorrhagic Complications in Patients Supported by Continuous-Flow Left Ventricular Assist Devices

Authors: Renzo Y. Loyaga-Rendon, Milena Jani, David Fermin, Jennifer K. McDermott, Diane Vancamp, Sangjin Lee

Published in: Current Heart Failure Reports | Issue 6/2017

Login to get access

Abstract

Purpose of Review

The purpose of this review is to describe the current knowledge in prevention and treatment of thrombotic (pump thrombosis and ischemic stroke) and bleeding (gastrointestinal and hemorrhagic stroke) complications in patients supported by continuous-flow left ventricular assist devices (CF-LVAD).

Recent Findings

Left ventricular assist devices (LVADs) are now widely used for the management of end-stage heart failure. Unfortunately, in spite of the indisputable positive impact LVADs have on patients, the frequency and severity of complications are limitations of this therapy. Stroke, pump thrombosis, and gastrointestinal bleeding are among the most serious and frequent complications in these patients.

Summary

The balance between hemorrhagic and thrombotic complications in patients supported with CF-LVAD is difficult as most patients do not necessarily fit a “bleeder” or a “clotter” profile but rather move from one side to the other of the thrombotic/bleeding spectrum. Further research is necessary to better understand the risk factors and mechanisms involved in the development of these complications.
Literature
1.
Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361(23):2241–51.CrossRefPubMed
2.
Rogers JG, Aaronson KD, Boyle AJ, Russell SD, Milano CA, Pagani FD, et al. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol. 2010;55(17):1826–34.CrossRefPubMed
3.
Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, et al. Seventh INTERMACS annual report: 15,000 patients and counting. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2015;34(12):1495–504.CrossRef
4.
John R, Kamdar F, Liao K, Colvin-Adams M, Boyle A, Joyce L. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy. Ann Thorac Surg 2008;86(4):1227–1234; discussion 34-5.
5.
Slaughter MS, Naka Y, John R, Boyle A, Conte JV, Russell SD, et al. Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2010;29(6):616–24.CrossRef
6.
Boyle AJ, Russell SD, Teuteberg JJ, Slaughter MS, Moazami N, Pagani FD, et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2009;28(9):881–7.CrossRef
7.
Starling RC, Moazami N, Silvestry SC, Ewald G, Rogers JG, Milano CA, et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med. 2014;370(1):33–40.CrossRefPubMed
8.
Kirklin JK, Naftel DC, Kormos RL, Pagani FD, Myers SL, Stevenson LW, et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2014;33(1):12–22.CrossRef
9.
Mehra MR, Stewart GC, Uber PA. The vexing problem of thrombosis in long-term mechanical circulatory support. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2014;33(1):1–11.CrossRef
10.
Stulak JM, Lee D, Haft JW, Romano MA, Cowger JA, Park SJ, et al. Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2014;33(1):60–4.CrossRef
11.
Katz JN, Adamson RM, John R, Tatooles A, Sundareswaran K, Kallel F, et al. Safety of reduced anti-thrombotic strategies in HeartMate II patients: a one-year analysis of the US-TRACE Study. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2015;34(12):1542–8.CrossRef
12.
Starling RC, Naka Y, Boyle AJ, Gonzalez-Stawinski G, John R, Jorde U, et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2011;57(19):1890–8.CrossRefPubMed
13.
Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Myers S, Acker MA, et al. Pump thrombosis in the Thoratec HeartMate II device: an update analysis of the INTERMACS Registry. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2015;34(12):1515–26.CrossRef
14.
Najjar SS, Slaughter MS, Pagani FD, Starling RC, McGee EC, Eckman P, et al. An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2014;33(1):23–34.CrossRef
15.
Goldstein DJ, John R, Salerno C, Silvestry S, Moazami N, Horstmanshof D, et al. Algorithm for the diagnosis and management of suspected pump thrombus. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2013;32(7):667–70.CrossRef
16.
Maltais S, Kilic A, Nathan S, Keebler M, Emani S, Ransom J, et al. PREVENtion of HeartMate II pump thrombosis through clinical management: the PREVENT multi-center study. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2017;36(1):1–12.CrossRef
17.
• Mehra MR, Naka Y, Uriel N, Goldstein DJ, Cleveland JC Jr, Colombo PC, et al. A fully magnetically levitated circulatory pump for advanced heart failure. N Engl J Med. 2017;376(5):440–50. This publication demonstrates the decreased rates of LVAD thrombosis with a new axial CF-LVAD. CrossRefPubMed
18.
Thomas MD, Wood C, Lovett M, Dembo L, O'Driscoll G. Successful treatment of rotary pump thrombus with the glycoprotein IIb/IIIa inhibitor tirofiban. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2008;27(8):925–7.CrossRef
19.
Al-Quthami AH, Jumean M, Kociol R, Pham DT, Kiernan M, DeNofrio D, et al. Eptifibatide for the treatment of HeartMate II left ventricular assist device thrombosis. Circulation Heart failure. 2012;5(4):e68–70.CrossRefPubMed
20.
Badiye A, Hernandez GA, Chaparro S. Argatroban as novel therapy for suspected thrombosis in patients with continuous-flow left ventricle assist device and hemolysis. ASAIO journal (American Society for Artificial Internal Organs : 1992). 2014;60(3):361–5.CrossRef
21.
Sylvia LM, Ordway L, Pham DT, DeNofrio D, Kiernan M. Bivalirudin for treatment of LVAD thrombosis: a case series. ASAIO journal (American Society for Artificial Internal Organs : 1992). 2014;60(6):744–7.CrossRef
22.
Kamouh A, John R, Eckman P. Successful treatment of early thrombosis of HeartWare left ventricular assist device with intraventricular thrombolytics. Ann Thorac Surg. 2012;94(1):281–3.CrossRefPubMed
23.
Schlendorf K, Patel CB, Gehrig T, Kiefer TL, Felker GM, Hernandez AF, et al. Thrombolytic therapy for thrombosis of continuous flow ventricular assist devices. J Card Fail. 2014;20(2):91–7.CrossRefPubMed
24.
Tellor BR, Smith JR, Prasad SM, Joseph SM, Silvestry SC. The use of eptifibatide for suspected pump thrombus or thrombosis in patients with left ventricular assist devices. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2014;33(1):94–101.CrossRef
25.
Bellumkonda L, Subrahmanyan L, Jacoby D, Bonde P. Left ventricular assist device pump thrombosis: is there a role for glycoprotein IIb/IIIa inhibitors? ASAIO journal (American Society for Artificial Internal Organs : 1992). 2014;60(1):134–6.CrossRef
26.
Stulak JM, Dunlay SM, Sharma S, Haglund NA, Davis MB, Cowger J, et al. Treatment of device thrombus in the HeartWare HVAD: success and outcomes depend significantly on the initial treatment strategy. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2015;34(12):1535–41.CrossRef
27.
Moazami N, Milano CA, John R, Sun B, Adamson RM, Pagani FD, et al. Pump replacement for left ventricular assist device failure can be done safely and is associated with low mortality. Ann Thorac Surg. 2013;95(2):500–5.CrossRefPubMed
28.
Jorde UP, Aaronson KD, Najjar SS, Pagani FD, Hayward C, Zimpfer D, et al. Identification and management of pump thrombus in the HeartWare left ventricular assist device system: a novel approach using log file analysis. JACC Heart failure. 2015;3(11):849–56.CrossRefPubMed
29.
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Executive summary: heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133(4):447–54.CrossRefPubMed
30.
• Acharya D, L-R R, Morgan CJ, Sands KA, Pamboukian SV, Rajapreyar I, Holman WL, Kirklin JK, Tallaj JA. INTERMACS analysis of stroke during support with continuous-flow left ventricular assist devices: risk factors and outcomes. JACC Heart Fail. 2017. Oct 5 (10) 703–711. This is the most recent publication on the characteristics of stroke in CF-LVAD patients obtained from the INTERMACS.
31.
Harvey L, Holley C, Roy SS, Eckman P, Cogswell R, Liao K, et al. Stroke after left ventricular assist device implantation: outcomes in the continuous-flow era. Ann Thorac Surg. 2015;100(2):535–41.CrossRefPubMed
32.
33.
Hemphill JC 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46(7):2032–60.CrossRefPubMed
34.
Kim JH, Singh R, Pagani FD, Desai SS, Haglund NA, Dunlay SM, et al. Ventricular assist device therapy in older patients with heart failure: characteristics and outcomes. J Card Fail. 2016;22(12):981–7.CrossRefPubMed
35.
Boyle AJ, Jorde UP, Sun B, Park SJ, Milano CA, Frazier OH, et al. Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. J Am Coll Cardiol. 2014;63(9):880–8.CrossRefPubMed
36.
Meeteren JV, Maltais S, Dunlay SM, Haglund NA, Beth Davis M, Cowger J, et al. A multi-institutional outcome analysis of patients undergoing left ventricular assist device implantation stratified by sex and race. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2017;36(1):64–70.CrossRef
37.
Musunuru K, Hickey KT, Al-Khatib SM, Delles C, Fornage M, Fox CS, et al. Basic concepts and potential applications of genetics and genomics for cardiovascular and stroke clinicians: a scientific statement from the American Heart Association. Circ Cardiovasc Genet. 2015;8(1):216–42.CrossRefPubMedPubMedCentral
38.
Fried J, Levin AP, Mody KM, Garan AR, Yuzefpolsakaya M, Takayama H, et al. Prior hematologic conditions carry a high morbidity and mortality in patients supported with continuous-flow left ventricular assist devices. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2014;33(11):1119–25.CrossRef
39.
Alvarez P, Cordero-Reyes AM, Uribe C, De Hoyos P, Martinez D, Bhimaraj A, et al. Acquired and hereditary hypercoagulable states in patients with continuous flow left ventricular assist devices: prevalence and thrombotic complications. J Card Fail. 2016;22(7):501–11.CrossRefPubMed
40.
Bennett MK, Roberts CA, Dordunoo D, Shah A, Russell SD. Ideal methodology to assess systemic blood pressure in patients with continuous-flow left ventricular assist devices. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2010;29(5):593–4.CrossRef
41.
Lampert BC, Eckert C, Weaver S, Scanlon A, Lockard K, Allen C, et al. Blood pressure control in continuous flow left ventricular assist devices: efficacy and impact on adverse events. Ann Thorac Surg. 2014;97(1):139–46.CrossRefPubMed
42.
Nassif ME, Tibrewala A, Raymer DS, Andruska A, Novak E, Vader JM, et al. Systolic blood pressure on discharge after left ventricular assist device insertion is associated with subsequent stroke. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2015;34(4):503–8.CrossRef
43.
Frontera JA, Starling R, Cho SM, Nowacki AS, Uchino K, Hussain MS, et al. Risk factors, mortality, and timing of ischemic and hemorrhagic stroke with left ventricular assist devices. J Heart Lung Transplant. 2017;(6):673–683.
44.
Vest AR, Mistak SM, Hachamovitch R, Mountis MM, Moazami N, Young JB. Outcomes for patients with diabetes after continuous-flow left ventricular assist device implantation. J Card Fail. 2016;22(10):789–96.CrossRefPubMed
45.
Willey JZ, Gavalas MV, Trinh PN, Yuzefpolskaya M, Reshad Garan A, Levin AP, et al. Outcomes after stroke complicating left ventricular assist device. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2016;35(8):1003–9.CrossRef
46.
Xuereb L, Go PH, Kaur B, Akrawe S, Nemeh HW, Borgi J, et al. Impact of preoperative atrial fibrillation on postoperative thromboembolic events after left ventricular assist device implantation. Ann Thorac Surg. 2016;102(5):1543–9.CrossRefPubMed
47.
Enriquez AD, Calenda B, Gandhi PU, Nair AP, Anyanwu AC, Pinney SP. Clinical impact of atrial fibrillation in patients with the HeartMate II left ventricular assist device. J Am Coll Cardiol. 2014;64(18):1883–90.CrossRefPubMed
48.
Stulak JM, Deo S, Schirger J, Aaronson KD, Park SJ, Joyce LD, et al. Preoperative atrial fibrillation increases risk of thromboembolic events after left ventricular assist device implantation. Ann Thorac Surg. 2013;96(6):2161–7.CrossRefPubMed
49.
Go PH, Nemeh HW, Borgi J, Paone G, Morgan JA. Effect of body mass index on outcomes in left ventricular assist device recipients. J Card Surg. 2016;31(4):242–7.CrossRefPubMed
50.
Komoda T, Drews T, Hetzer R, Lehmkuhl HB. Lower body surface area is highly related to mortality due to stroke or systemic bleeding in patients receiving an axial flow blood pump as a left ventricular assist device. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2013;43(5):1036–42.CrossRef
51.
Lee S, Katz JN, Jorde UP, Moazami N, John R, Sundareswaran KS, et al. Outcomes of adult patients with small body size supported with a continuous-flow left ventricular assist device. ASAIO journal (American Society for Artificial Internal Organs : 1992). 2016;62(6):646–51.CrossRefPubMedCentral
52.
Zittermann A, Morshuis M, Kuhn J, Pilz S, Ernst JB, Oezpeker C, et al. Vitamin D metabolites and fibroblast growth factor-23 in patients with left ventricular assist device implants: association with stroke and mortality risk. Eur J Nutr. 2016;55(1):305–13.CrossRefPubMed
53.
Lazar RM, Shapiro PA, Jaski BE, Parides MK, Bourge RC, Watson JT, et al. Neurological events during long-term mechanical circulatory support for heart failure: the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) experience. Circulation. 2004;109(20):2423–7.CrossRefPubMed
54.
Slaughter MS, Pagani FD, McGee EC, Birks EJ, Cotts WG, Gregoric I, et al. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2013;32(7):675–83.CrossRef
55.
Stulak JM, Davis ME, Haglund N, Dunlay S, Cowger J, Shah P, et al. Adverse events in contemporary continuous-flow left ventricular assist devices: a multi-institutional comparison shows significant differences. J Thorac Cardiovasc Surg. 2016;151(1):177–89.CrossRefPubMed
56.
Coffin ST, Haglund NA, Davis ME, Xu M, Dunlay SM, Cowger JA, et al. Adverse neurologic events in patients bridged with long-term mechanical circulatory support: a device-specific comparative analysis. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2015;34(12):1578–85.CrossRef
57.
Morris AA, Pekarek A, Wittersheim K, Cole RT, Gupta D, Nguyen D, et al. Gender differences in the risk of stroke during support with continuous-flow left ventricular assist device. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2015;34(12):1570–7.CrossRef
58.
Lalonde SD, Alba AC, Rigobon A, Ross HJ, Delgado DH, Billia F, et al. Clinical differences between continuous flow ventricular assist devices: a comparison between HeartMate II and HeartWare HVAD. J Card Surg. 2013;28(5):604–10.CrossRefPubMed
59.
Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, et al. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med. 2017;376(5):451–60.CrossRefPubMed
60.
Zhang Y, Gao B, Yu C. The hemodynamic effects of the LVAD outflow cannula location on the thrombi distribution in the aorta: a primary numerical study. Comput Methods Prog Biomed. 2016;133:217–27.CrossRef
61.
Bhat S, Mathews J, Balakrishnan KR, Krishna KR. Effect of outflow graft size on flow in the aortic arch and cerebral blood flow in continuous flow pumps: possible relevance to strokes. ASAIO 2017;63(2):144–149.
62.
Osorio AF, Osorio R, Ceballos A, Tran R, Clark W, Divo EA, et al. Computational fluid dynamics analysis of surgical adjustment of left ventricular assist device implantation to minimise stroke risk. Computer methods in biomechanics and biomedical engineering. 2013;16(6):622–38.CrossRefPubMed
63.
Trachtenberg BH, Cordero-Reyes AM, Aldeiri M, Alvarez P, Bhimaraj A, Ashrith G, et al. Persistent blood stream infection in patients supported with a continuous-flow left ventricular assist device is associated with an increased risk of cerebrovascular accidents. J Card Fail. 2015;21(2):119–25.CrossRefPubMed
64.
Aggarwal A, Gupta A, Kumar S, Baumblatt JA, Pauwaa S, Gallagher C, et al. Are blood stream infections associated with an increased risk of hemorrhagic stroke in patients with a left ventricular assist device? ASAIO journal (American Society for Artificial Internal Organs : 1992). 2012;58(5):509–13.CrossRef
65.
Jennings DL, Jacob M, Chopra A, Nemerovski CW, Morgan JA, Lanfear DE. Safety of anticoagulation reversal in patients supported with continuous-flow left ventricular assist devices. ASAIO journal (American Society for Artificial Internal Organs : 1992). 2014;60(4):381–4.CrossRef
66.
Wong JK, Chen PC, Falvey J, Melvin AL, Lidder AK, Lowenstein LM, et al. Anticoagulation reversal strategies for left ventricular assist device patients presenting with acute intracranial hemorrhage. ASAIO journal (American Society for Artificial Internal Organs : 1992). 2016;62(5):552–7.CrossRef
67.
Bradford CD, Stahovich MJ, Dembitsky WP, Adamson RM, Engelbert JJ, Perreiter AS. Safety of prothombin complex concentrate to control excess bleeding during continuous flow LVAD insertion. ASAIO journal (American Society for Artificial Internal Organs : 1992). 2015;61(5):509–13.CrossRef
68.
Al-Mufti F, Bauerschmidt A, Claassen J, Meyers PM, Colombo PC, Willey JZ. Neuroendovascular interventions for acute ischemic strokes in patients supported with left ventricular assist devices: a single-center case series and review of the literature. World neurosurgery. 2016;88:199–204.CrossRefPubMed
69.
Morgan JA, Paone G, Nemeh HW, Henry SE, Patel R, Vavra J, et al. Gastrointestinal bleeding with the HeartMate II left ventricular assist device. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2012;31(7):715–8.CrossRef
70.
Holley CT, Harvey L, Roy SS, Cogswell R, Eckman P, Liao K, et al. Gastrointestinal bleeding during continuous-flow left ventricular assist device support is associated with lower rates of cardiac transplantation. ASAIO journal (American Society for Artificial Internal Organs : 1992). 2015;61(6):635–9.CrossRef
71.
Joy PS, Kumar G, Guddati AK, Bhama JK, Cadaret LM. Risk factors and outcomes of gastrointestinal bleeding in left ventricular assist device recipients. Am J Cardiol. 2016;117(2):240–4.CrossRefPubMed
72.
Sparrow CT, Nassif ME, Raymer DS, Novak E, LaRue SJ, Schilling JD. Pre-operative right ventricular dysfunction is associated with gastrointestinal bleeding in patients supported with continuous-flow left ventricular assist devices. JACC Heart failure. 2015;3(12):956–64.CrossRefPubMed
73.
Wever-Pinzon O, Selzman CH, Drakos SG, Saidi A, Stoddard GJ, Gilbert EM, et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circulation Heart failure. 2013;6(3):517–26.CrossRefPubMed
74.
Jabbar HR, Abbas A, Ahmed M, Klodell CT Jr, Chang M, Dai Y, et al. The incidence, predictors and outcomes of gastrointestinal bleeding in patients with left ventricular assist device (LVAD). Dig Dis Sci. 2015;60(12):3697–706.CrossRefPubMed
75.
Saito S, Yamazaki K, Nishinaka T, Ichihara Y, Ono M, Kyo S, et al. Post-approval study of a highly pulsed, low-shear-rate, continuous-flow, left ventricular assist device, EVAHEART: a Japanese multicenter study using J-MACS. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2014;33(6):599–608.CrossRef
76.
Houston BA, Schneider AL, Vaishnav J, Cromwell DM, Miller PE, Faridi KF, et al. Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. J Heart Lung Transplant. 2017;(4):380–385.
77.
Hanson BJ, Koene RJ, Roy SS, Eckman PM, John R, Chaudhary NA, et al. Safety and outcomes of capsule endoscopy in patients with left ventricular assist device: a single-center retrospective case series. J Cardiovasc Transl Res. 2016;9(4):402–4.CrossRefPubMed
78.
Amornsawadwattana S, Nassif M, Raymer D, LaRue S, Chen CH. Video capsule endoscopy in left ventricular assist device recipients with obscure gastrointestinal bleeding. World J Gastroenterol. 2016;22(18):4559–66.CrossRefPubMedPubMedCentral
79.
Cochrane J, Jackson C, Schlepp G, Strong R. Gastrointestinal angiodysplasia is associated with significant gastrointestinal bleeding in patients with continuous left ventricular assist devices. Endoscopy international open. 2016;4(3):E371–7.CrossRefPubMedPubMedCentral
80.
Dang G, Grayburn R, Lamb G, Umpierrez De Regureo A, Gaglianello N. Octreotide for the management of gastrointestinal bleeding in a patient with a heartware left ventricular assist device. Case Rep Cardiol. 2014; 2014:826453. https://​doi.​org/​10.​1155/​2014/​826453
81.
Rennyson S, Shah K, Tang D, Kasirajan V, Pedram, S, Cahoon W, Malhora, R. Octreotide for left ventricular assist device-related gastrointestinal hemorrhage: Can we stop the bleeding? ASAIO J. 2013;59(4):450–451.
82.
Loyaga-Rendon RY, Hashim T, Tallaj JA, Acharya D, Holman W, Kirklin J, et al. Octreotide in the management of recurrent gastrointestinal bleed in patients supported by continuous flow left ventricular assist devices. ASAIO journal (American Society for Artificial Internal Organs : 1992). 2015;61(1):107–9.CrossRef
83.
Malhotra R, Shah KB, Chawla R, Pedram S, Smallfield MC, Profay AG et al. Tolerability and biological effects of long-acting octreotide in patients with continuous flow left ventricular assist devices. ASAIO. 2017;63(3):367–370.
84.
Brown C, Subramanian V, Wilcox CM, Peter S. Somatostatin analogues in the treatment of recurrent bleeding from gastrointestinal vascular malformations: an overview and systematic review of prospective observational studies. Dig Dis Sci. 2010;55(8):2129–34.CrossRefPubMed
85.
Malhotra R, Shah KB, Chawla R, Pedram S, Smallfield MC, Priday AG, et al. Tolerability and biological effects of long acting octreotide in patients with continuous flow left ventricular assist devices. ASAIO J (American Society for Artificial Internal Organs: 1992). 2016.
86.
Schettle SD, Pruthi RK, Pereira NL. Continuous-flow left ventricular assist devices and gastrointestinal bleeding: potential role of danazol. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2014;33(5):549–50.CrossRef
87.
Szilagyi A, Ghali MP. Pharmacological therapy of vascular malformations of the gastrointestinal tract. Canadian journal of gastroenterology = Journal canadien de gastroenterologie 2006;20(3):171–178.
88.
Kushnir VM, Sharma S, Ewald GA, Seccombe J, Novak E, Wang IW, et al. Evaluation of GI bleeding after implantation of left ventricular assist device. Gastrointest Endosc. 2012;75(5):973–9.CrossRefPubMed
89.
90.
Ge ZZ, Chen HM, Gao YJ, Liu WZ, Xu CH, Tan HH, et al. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology. 2011;141(5):1629–37.e1-4.CrossRefPubMed
91.
Tan HH, Ge ZZ, Chen HM, Gao YJ. Successful treatment with thalidomide for a patient with recurrent gastrointestinal bleeding due to angiodysplasia diagnosed by capsule endoscopy. J Dig Dis. 2013;14(3):153–5.CrossRefPubMed
92.
Chan LL, Lim CP, Lim CH, Tan TE, Sim D, Sivathasan C. Novel use of thalidomide in recurrent gastrointestinal tract bleeding in patients with left ventricular assist devices: a case series. Heart Lung Circ. 2016;26(10):1101–1104.
93.
Ray R, Kale P, Ha R, Banerjee D. Treatment of left ventricular assist device-associated arteriovenous malformation with thalidomide. ASAIO J. 2014;60(4):482–483.
94.
Hollis IB, Chen SL, Chang PP, Katz JN. Inhaled desmopressin for refractory gastrointestinal bleeding in a patient with a HeartMate II left ventricular assist device. ASAIO journal (American Society for Artificial Internal Organs: 1992). 2017;63(4):e47–e9.x
95.
Bartoli CR, Kang J, Restle DJ, Zhang DM, Shabahang C, Acker MA, et al. Inhibition of ADAMTS-13 by doxycycline reduces von Willebrand factor degradation during supraphysiological shear stress: therapeutic implications for left ventricular assist device-associated bleeding. JACC Heart failure. 2015;3(11):860–9.CrossRefPubMed
Metadata
Title
Prevention and Treatment of Thrombotic and Hemorrhagic Complications in Patients Supported by Continuous-Flow Left Ventricular Assist Devices
Authors
Renzo Y. Loyaga-Rendon
Milena Jani
David Fermin
Jennifer K. McDermott
Diane Vancamp
Sangjin Lee
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Heart Failure Reports / Issue 6/2017
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-017-0367-3

Other articles of this Issue 6/2017

Current Heart Failure Reports 6/2017 Go to the issue

Genetics of Heart Failure (K Adams, Section Editor)

Pharmacogenomics of the Natriuretic Peptide System in Heart Failure

Prevention of Heart Failure (M. St. John Sutton, Section Editor)

High-Risk Percutaneous Coronary Intervention in Public Reporting States: the Evidence, Exclusion of Critically Ill Patients, and Implications

Genetics of Heart Failure (K Adams, Section Editor)

Clinical Application of Genetic Testing in Heart Failure

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (S Katz, Section Editor)

Skeletal muscle alterations in HFrEF vs. HFpEF

Pharmacologic Therapy (W H W Tang, Section Editor)

MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential

Prevention of Heart Failure (M. St. John Sutton, Section Editor)

Defining Ambulatory Advanced Heart Failure: MedaMACS and Beyond
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits